Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT00946673
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vorinostat — DRUG
    Orally up to 400 mg
  • Radiation Therapy — PROCEDURE
    Single fraction stereotactic radiotherapy - Standard of Care

Study Details

The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.

Key Dates

Start date
Jun 30, 2009
Status verified
Oct 2017
Primary completion
Jul 31, 2014
Completion
Jul 31, 2015

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: vorinostat & stereotactic radiosurgery

Primary Outcome Measure

The maximum tolerated dose of vorinostat with concurrent radiosurgery will be determined. [ Time Frame: 30 days following Stereotactic Radiosurgery ]

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-
Moffitt Cancer CenterTampaFlorida33612-

Find similar trials in Stanford, CA

By condition
Brain cancerLung cancer
By specialty
OncologyNeuro-oncologyLung oncologyLung disease
By research site
Stanford University School of Medicine· Stanford, CAMoffitt Cancer Center· Tampa, FL

Related Studies